Kalmus P, Simojoki H, Orro T, Taponen S, Mustonen K, Holopainen J, Pyörälä S
Department of Therapy, Institute of Veterinary Medicine and Animal Science, Estonian University of Life Sciences, Tartu, 51014, Estonia.
Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Paroninkuja 20, FI-04920 Saarentaus, Finland.
J Dairy Sci. 2014;97(4):2155-64. doi: 10.3168/jds.2013-7338. Epub 2014 Jan 31.
The efficacy of parenteral (intramuscular) or intramammary (IMM) benzylpenicillin treatment for clinical mastitis caused by gram-positive bacteria susceptible to penicillin in vitro was investigated. Cows with clinical mastitis in 1 udder quarter were randomly placed into 2 treatment groups. The preliminary bacteriological diagnosis of intramammary infection (IMI) was based on on-farm culturing, and the bacteriological diagnoses were later confirmed by a quantitative PCR assay. Clinical mastitis caused by gram-positive bacteria susceptible to benzylpenicillin was treated with penicillin via either the parenteral route (20mg/kg) or IMM route (600mg) once per day for 5d. The outcome of the treatment was evaluated 3 to 4wk after the onset of the treatment. The affected quarter was examined to assess the clinical cure, and milk samples were collected from the affected quarter to determine the bacteriological cure and milk N-acetyl-β-d-glucosaminidase activity. The survival and the composite milk somatic cell counts of the treated cows were followed up for 6 and 3mo after treatment, respectively. A total of 140 cows with clinical mastitis were included in the study, 61 being treated with benzylpenicillin parenterally and 79 via the IMM route. From all quarters treated, 108 of 140 (77.1%) were cured clinically and 77 of 140 (55.0%) were cured bacteriologically. The route of treatment did not significantly affect the outcome of the treatment; 80.3% of the quarters with parenteral treatment and 74.7% of the quarters with IMM treatment showed a clinical cure, and 54.1 and 55.7% a bacteriological cure, respectively. The milk N-acetyl-β-d-glucosaminidase activity was significantly lower in the quarters with a clinical or bacteriological cure than in the quarters with no cure. The 6-mo survival and the proportion of cows with composite milk somatic cell counts <200,000/mL among the treated cows during the 3-mo follow-up period did not significantly differ between the treatment groups. In conclusion, the outcome of either parenteral or IMM benzylpenicillin treatment of clinical mastitis caused by penicillin-susceptible bacteria was similar.
研究了肠胃外(肌肉注射)或乳房内(IMM)注射苄青霉素治疗由体外对青霉素敏感的革兰氏阳性菌引起的临床型乳腺炎的疗效。将1个乳房象限患有临床型乳腺炎的奶牛随机分为2个治疗组。乳房内感染(IMI)的初步细菌学诊断基于农场培养,随后通过定量PCR检测确认细菌学诊断。对由对苄青霉素敏感的革兰氏阳性菌引起的临床型乳腺炎,通过肠胃外途径(20mg/kg)或IMM途径(600mg)每天注射1次青霉素,持续5天。在治疗开始后3至4周评估治疗结果。检查患侧象限以评估临床治愈情况,并从患侧象限采集牛奶样本以确定细菌学治愈情况和牛奶N-乙酰-β-D-氨基葡萄糖苷酶活性。分别在治疗后6个月和3个月对治疗奶牛的存活情况和复合牛奶体细胞计数进行随访。共有140头患有临床型乳腺炎的奶牛纳入研究,其中61头通过肠胃外注射苄青霉素治疗,79头通过IMM途径治疗。在所有接受治疗的象限中,140个中有108个(77.1%)实现临床治愈,140个中有77个(55.0%)实现细菌学治愈。治疗途径对治疗结果没有显著影响;肠胃外治疗的象限中有80.3%实现临床治愈,IMM治疗的象限中有74.7%实现临床治愈,细菌学治愈率分别为54.1%和55.7%。临床或细菌学治愈的象限中牛奶N-乙酰-β-D-氨基葡萄糖苷酶活性显著低于未治愈的象限。在3个月的随访期内,治疗组之间的6个月存活率和复合牛奶体细胞计数<200,000/mL的奶牛比例没有显著差异。总之,肠胃外或IMM注射苄青霉素治疗由对青霉素敏感的细菌引起的临床型乳腺炎的结果相似。